Citation: | HOU Pengfei, HAN Xue, WANG Hong, JU Chao, ZHANG Fulan, HAO Lu. Application value of amide proton transfer combined with quantitative susceptibility mapping in the diagnosis of Parkinson's disease[J]. Journal of Molecular Imaging, 2024, 47(3): 225-230. doi: 10.12122/j.issn.1674-4500.2024.03.01 |
[1] |
Zheng ZL, Zhu ZY, Zhou C, et al. Burden of parkinson disease in China, 1990-2019: findings from the 2019 global burden of disease study[J]. Neuroepidemiology, 2023, 57(1): 51-64. doi: 10.1159/000527372
|
[2] |
Qi SG, Yin P, Wang LH, et al. Prevalence of Parkinson's disease: a community- based study in China[J]. Mov Disord, 2021, 36(12): 2940-4. doi: 10.1002/mds.28762
|
[3] |
Armstrong MJ, Okun MS. Diagnosis and treatment of parkinson disease: a review[J]. JAMA, 2020, 323(6): 548-60. doi: 10.1001/jama.2019.22360
|
[4] |
Tolosa E, Garrido A, Scholz SW, et al. Challenges in the diagnosis of Parkinson's disease[J]. Lancet Neurol, 2021, 20(5): 385-97. doi: 10.1016/S1474-4422(21)00030-2
|
[5] |
Li G, Ma JF, Cui SS, et al. Parkinson's disease in China: a forty-year growing track of bedside work[J]. Transl Neurodegener, 2019, 8: 22. doi: 10.1186/s40035-019-0162-z
|
[6] |
Harada T, Kudo K, Fujima N, et al. Quantitative susceptibility mapping: basic methods and clinical applications[J]. Radiographics, 2022, 42(4): 1161-76. doi: 10.1148/rg.210054
|
[7] |
Mahoney-Sánchez L, Bouchaoui H, Ayton S, et al. Ferroptosis and its potential role in the physiopathology of Parkinson's Disease[J]. Prog Neurobiol, 2021, 196: 101890. doi: 10.1016/j.pneurobio.2020.101890
|
[8] |
Shi LQ, Huang C, Luo QH, et al. The association of iron and the pathologies of Parkinson's diseases in MPTP/MPP +- induced neuronal degeneration in non- human Primates and in cell culture [J]. Front Aging Neurosci, 2019, 11: 215. doi: 10.3389/fnagi.2019.00215
|
[9] |
Ward RJ, Zucca FA, Duyn JH, et al. The role of iron in brain ageing and neurodegenerative disorders[J]. Lancet Neurol, 2014, 13(10): 1045-60. doi: 10.1016/S1474-4422(14)70117-6
|
[10] |
Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease[J]. J Neurochem, 1989, 52(6): 1830-6. doi: 10.1111/j.1471-4159.1989.tb07264.x
|
[11] |
米日班·买买提库尔班, 张树贤, 马景旭, 等. 酰胺质子转移磁共振成像在帕金森病中的研究进展[J]. 磁共振成像, 2023, 14(6): 94-8. https://www.cnki.com.cn/Article/CJFDTOTAL-CGZC202306016.htm
|
[12] |
Reichenbach JR, Schweser F, Serres B, et al. Quantitative susceptibility mapping: concepts and applications[J]. Clin Neuroradiol, 2015, 25(2): 225-30.
|
[13] |
王钧豪, 苏一飞, 成睿, 等. 酰胺质子转移成像在脑胶质瘤诊断及分子分型预测中的研究进展[J]. 分子影像学杂志, 2023, 46(4): 765-8. doi: 10.12122/j.issn.1674-4500.2023.04.33
|
[14] |
Koike H, Morikawa M, Ishimaru H, et al. Amide proton transfer-chemical exchange saturation transfer imaging of intracranial brain tumors and tumor- like lesions: our experience and a review[J]. Diagnostics, 2023, 13(5): 914. doi: 10.3390/diagnostics13050914
|
[15] |
Zhou JY, Heo HY, Knutsson L, et al. APT- weighted MRI: techniques, current neuro applications, and challenging issues[J]. J Magn Reson Imaging, 2019, 50(2): 347-64. doi: 10.1002/jmri.26645
|
[16] |
Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease[J]. Mov Disord, 2015, 30(12): 1591-601. doi: 10.1002/mds.26424
|
[17] |
陈永平, 商慧芳. 2016中国帕金森病诊断标准解读[J]. 中国实用内科杂志, 2017, 37(2): 124-6. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201702010.htm
|
[18] |
An HD, Zeng XY, Niu TF, et al. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping[J]. J Neurol Sci, 2018, 386: 46-52. doi: 10.1016/j.jns.2018.01.008
|
[19] |
Li KR, Avecillas-Chasin J, Nguyen TD, et al. Quantitative evaluation of brain iron accumulation in different stages of Parkinson's disease[J]. J Neuroimaging, 2022, 32(2): 363-71. doi: 10.1111/jon.12957
|
[20] |
Zhao QY, Tao YQ, Zhao K, et al. Structural insights of Fe3+ induced α-synuclein fibrillation in Parkinson's disease[J]. J Mol Biol, 2023, 435(1): 167680. doi: 10.1016/j.jmb.2022.167680
|
[21] |
Herman S, Djaldetti R, Mollenhauer B, et al. CSF- derived extracellular vesicles from patients with Parkinson's disease induce symptoms and pathology[J]. Brain, 2023, 146(1): 209-24. doi: 10.1093/brain/awac261
|
[22] |
Zhang JQ, Zhang YL, Wang J, et al. Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study[J]. Brain Res, 2010, 1330: 124-30. doi: 10.1016/j.brainres.2010.03.036
|
[23] |
Zhang Y, Wu IW, Buckley S, et al. Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease[J]. Mov Disord, 2015, 30 (9): 1229-36. doi: 10.1002/mds.26251
|
[24] |
Baumann CR, Held U, Valko PO, et al. Body side and predominant motor features at the onset of Parkinson's disease are linked to motor and nonmotor progression[J]. Mov Disord, 2014, 29(2): 207-13. doi: 10.1002/mds.25650
|
[25] |
Li CM, Chen M, Zhao XN, et al. Chemical exchange saturation transfer MRI signal loss of the substantia nigra as an imaging biomarker to evaluate the diagnosis and severity of Parkinson's disease[J]. Front Neurosci, 2017, 11: 489. doi: 10.3389/fnins.2017.00489
|
[26] |
Li CM, Wang R, Chen HB, et al. Chemical exchange saturation transfer MR imaging is superior to diffusion-tensor imaging in the diagnosis and severity evaluation of Parkinson's disease: a study on substantia nigra and Striatum[J]. Front Aging Neurosci, 2015, 7: 198.
|
[27] |
Zhao YJ, Wee HL, Chan YH, et al. Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times[J]. Mov Disord, 2010, 25(6): 710-6. doi: 10.1002/mds.22875
|